


PERSONAL
INFORMATION

Carlo Capalbo

 +390633775800 carlo.capalbo@uniroma1.it

Date of birth 04/11/1977 | Nationality Italian

PRINCIPAL AREAS OF
EXPERTISE

Precision medicine in oncology; translational medicine in oncology; breast cancer; familial/hereditary breast cancer and BRCA mutations; innovative molecular techniques for the detection of genes mutations in hereditary cancers and clinical management of families with BRCA; target therapy in solid tumors; treatment of breast cancer, melanoma, lung, colorectal and CNS cancers; supportive and palliative care in cancer patients.

WORK EXPERIENCE

Dates: from Mar 2019 - To date

Name and address of employer: Department of Molecular Medicine – Sapienza University of Rome - Medical Oncology Unit, Sant'Andrea Hospital - Via di Grottarossa 1035, 00189 Rome, Italy.

Type of business or sector: Medical Oncology.

Occupation or position: Researcher RTDB - M.D.

Main activities and responsibilities: treatment of solid tumors and precision medicine research field(s): Precision medicine and hereditary cancers

Dates: from Jan 2018 - Feb 2019

Name and address of employer: Medical Oncology Unit, Sant'Andrea Hospital - Via di Grottarossa 1035, 00189 Rome, Italy.

Type of business or sector: Medical Oncology.

Occupation or position: M.D.

Main activities and responsibilities: treatment of solid tumors and precision medicine research field(s): Precision medicine and hereditary cancers

Dates: from Jan 2013 - Dec 2017

Name and address of employer: Department of Molecular Medicine – Sapienza University of Rome - Medical Oncology Unit, Sant'Andrea Hospital - Via di Grottarossa 1035, 00189 Rome, Italy.

Type of business or sector: Medical Oncology.

Occupation or position: Researcher RTDA - M.D.

Main activities and responsibilities: treatment of solid tumors and precision medicine research field(s): Precision medicine and hereditary cancers

Dates: from Aug 2007 - Dec 2012

Name and address of employer: IDI - IRCCS (recognised by the Italian Ministry of Health as a Scientific Institute carrying out biomedical research and clinical activities of relevant national interest).

Type of business or sector: Medical Oncology.

Occupation or position: M.D.

Main activities and responsibilities: treatment of solid tumors and precision medicine research field(s): Precision medicine and hereditary cancers

EDUCATION AND TRAINING

Dates: Jul 2002

Name and type of organization providing education and training: School of Medicine, Sapienza University of Rome, Italy 110/110 cum laude
 Title of qualification awarded: M.D.

Dates: Oct 2006

Name and type of organization providing education and training: Postgraduate Course in Oncology, Sapienza University of Rome, Italy
 Title of qualification awarded: Specialist in Oncology 70/70 cum laude

Dates: Mar 2011

Name and type of organization providing education and training: Doctoral Degrees in Endocrinology and Molecular Medicine, Sapienza University of Rome, Italy
 Title of qualification awarded: PhD

PERSONAL SKILLS

Mother tongue(s) Italian

Other language(s)	English		
	UNDERSTANDING VERY GOOD	SPEAKING GOOD	WRITING VERY GOOD

Digital skills

MAC OS Good Knowledge of word processing software (Word for MAC, Pages), presentation software (Power Point for MAC, Keynote) and spreadsheet software (Excel for MAC, Numbers)

Microsoft OS Good Knowledge of word processing software (Microsoft Word), presentation software (Microsoft Power Point) and spreadsheet software (Microsoft Excel). Expertise on statistics/ database software (Microsoft Excel/Access).

ADDITIONAL INFORMATION

- 2011 Elected National WG member (under 40) at AIOM (the Italian Association of Medical Oncology)
- 2015 Nominated Expert in Medical Oncology, in support of the activities of the Italian Medicines Agency (AIFA, the national authority responsible for drugs regulation in Italy).

ANNEXES PUBLICATIONS

Phenformin Inhibits Hedgehog-Dependent Tumor Growth through a Complex I-Independent Redox/Corepressor Module.

Di Magno L, Manni S, Di Pastena F, Coni S, Macone A, Cairoli S, Sambucci M, Infante P, Moretti M, Petroni M, Nicoletti C, **Capalbo C**, De Smaele E, Di Marcotullio L, Giannini G, Battistini L, Goffredo BM, Iorio E, Agostinelli E, Maroder M, Canettieri G.

Cell Rep. 2020 Feb 11;30(6):1735-1752.e7. doi: 10.1016/j.celrep.2020.01.024. IF: 7.8

Applications of Next Generation Sequencing to the Analysis of Familial Breast/Ovarian Cancer.

Zelli V, Compagnoni C, Cannita K, Capelli R, **Capalbo C**, Di Vito Nolfi M, Alesse E, Zazzeroni F, Tessitore A. High Throughput. 2020 Jan 10;9(1). pii: E1. doi: 10.3390/ht9010001. Review. IF:1

PMID:

SMO-M2 mutation does not support cell-autonomous Hedgehog activity in cerebellar granule cell precursors.

Petroni M, Sahùn Roncero M, Ramponi V, Fabretti F, Nicolis Di Robilant V, Moretti M, Alfano V, Corsi A, De Panfilis S, Giubettini M, Di Giulio S, **Capalbo C**, Belardinilli F, Coppa A, Sardina F, Colicchia V, Pedretti F, Infante P, Cardinali B, Tessitore A, Canettieri G, De Smaele E, Giannini G.

Sci Rep. 2019 Dec 23;9(1):19623. doi: 10.1038/s41598-019-56057-y. IF: 4

Identification of novel BRCA1 large genomic rearrangements by a computational algorithm of amplicon-based Next-Generation Sequencing data.

Nicolussi A, Belardinilli F, Silvestri V, Mahdavian Y, Valentini V, D'Inzeo S, Petroni M, Zani M, Ferraro S, Di Giulio S, Fabretti F, Fratini B, Gradilone A, Ottini L, Giannini G, Coppa A, **Capalbo C**.

PeerJ. 2019 Nov 15;7:e7972. doi: 10.7717/peerj.7972. eCollection 2019. IF:2.3

Kras/ADAM17-Dependent Jag1-ICD Reverse Signaling Sustains Colorectal Cancer Progression and Chemoresistance.

Pelullo M, Nardoza F, Zema S, Quaranta R, Nicoletti C, Besharat ZM, Felli MP, Cerbelli B, d'Amati G, Palermo R, **Capalbo C**, Talora C, Di Marcotullio L, Giannini G, Checquolo S, Screpanti I, Bellavia D.

Cancer Res. 2019 Nov 1;79(21):5575-5586. doi: 10.1158/0008-5472.CAN-19-0145. Epub 2019 Sep 10. IF:8.3

ERAP1 promotes Hedgehog-dependent tumorigenesis by controlling USP47-mediated degradation of βTrCP.

Bufalieri F, Infante P, Bernardi F, Caimano M, Romania P, Moretti M, Lospinoso Severini L, Talbot J, Melaiu O, Tanori M, Di Magno L, Bellavia D, **Capalbo C**, Puget S, De Smaele E, Canettieri G, Guardavaccaro D, Busino L, Peschiaroli A, Pazzaglia S, Giannini G, Melino G, Locatelli F, Gulino A, Ayrault O, Fruci D, Di Marcotullio L.

Nat Commun. 2019 Jul 24;10(1):3304. doi: 10.1038/s41467-019-11093-0. IF:11.8

Next-generation sequencing of BRCA1 and BRCA2 genes for rapid detection of germline mutations in hereditary breast/ovarian cancer.

Nicolussi A, Belardinilli F, Mahdavian Y, Colicchia V, D'Inzeo S, Petroni M, Zani M, Ferraro S, Valentini V, Ottini L, Giannini G, **Capalbo C***, Coppa A*.

PeerJ. 2019 Apr 22;7:e6661. doi: 10.7717/peerj.6661. eCollection 2019. IF:2.3

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs.

Capalbo C, Scafetta G, Filetti M, Marchetti P, Bartolazzi A.

Int J Mol Sci. 2019 Mar 31;20(7). pii: E1607. doi: 10.3390/ijms20071607. IF: 4.1

A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal Cancer.

Capalbo C, Belardinilli F, Raimondo D, Milanetti E, Malapelle U, Pisapia P, Magri V, Prete A, Pecorari S, Colella M, Coppa A, Bonfiglio C, Nicolussi A, Valentini V, Tessitore A, Cardinali B, Petroni M, Infante P, Santoni M, Filetti M, Colicchia V, Paci P, Mezi S, Longo F, Cortesi E, Marchetti P, Troncone G, Bellavia D, Canettieri G, Giannini G.

Cancers (Basel). 2019 Jan 27;11(2). pii: E147. doi: 10.3390/cancers11020147. IF: 6.1

Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy.

Rizzolo P, Zelli V, Silvestri V, Valentini V, Zanna I, Bianchi S, Masala G, Spinelli AM, Tibiletti MG, Russo A, Varesco L, Giannini G, **Capalbo C**, Calistri D, Cortesi L, Viel A, Bonanni B, Azzollini J, Manoukian S, Montagna M, Peterlongo P, Radice P, Palli D, Ottini L.

Int J Cancer. 2019 Jul 15;145(2):390-400. doi: 10.1002/ijc.32106. Epub 2019 Jan 24. iF: 4.9

Mitogen-activated kinase kinase kinase 1 inhibits hedgehog signaling and medulloblastoma growth through GLI1 phosphorylation.

Antonucci L, Di Magno L, D'Amico D, Manni S, Serrao SM, Di Pastena F, Bordone R, Yurtsever ZN, Caimano M, Petroni M, Giorgi A, Schininà ME, Yates Ii JR, Di Marcotullio L, De Smaele E, Checquolo S, **Capalbo C**, Agostinelli E, Maroder M, Coni S, Canettieri G.

Int J Oncol. 2019 Feb;54(2):505-514. doi: 10.3892/ijo.2018.4638. Epub 2018 Nov 19. IF: 3.5

MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors.

Petroni M, Sardina F, Infante P, Bartolazzi A, Locatelli E, Fabretti F, Di Giulio S, **Capalbo C**, Cardinali B, Coppa A, Tessitore A, Colicchia V, Sahùn Roncero M, Belardinilli F, Di Marcotullio L, Soddu S, Comes Franchini M, Petricci E, Gulino A, Giannini G.

Cell Death Dis. 2018 Aug 30;9(9):895. doi: 10.1038/s41419-018-0924-z. IF:5.9

Effective treatment of a platinum-resistant cutaneous squamous cell carcinoma case by EGFR pathway inhibition.

Capalbo C, Belardinilli F, Filetti M, Parisi C, Petroni M, Colicchia V, Tessitore A, Santoni M, Coppa A, Giannini G, Marchetti P.

Mol Clin Oncol. 2018 Jul;9(1):30-34. doi: 10.3892/mco.2018.1634. Epub 2018 May 21.

NOTCH3 inactivation increases triple negative breast cancer sensitivity to gefitinib by promoting EGFR tyrosine dephosphorylation and its intracellular arrest.

Diluvio G, Del Gaudio F, Giuli MV, Franciosa G, Giuliani E, Palermo R, Besharat ZM, Pignataro MG, Vacca A, d'Amati G, Maroder M, Talora C, **Capalbo C**, Bellavia D, Checquolo S.

Oncogenesis. 2018 May 25;7(5):42. doi: 10.1038/s41389-018-0051-9. IF: 5.9

Itch/ β -arrestin2-dependent non-proteolytic ubiquitylation of SuFu controls Hedgehog signalling and

medulloblastoma tumorigenesis.

Infante P, Faedda R, Bernardi F, Bufalieri F, Lospinoso Severini L, Alfonsi R, Mazzà D, Siler M, Coni S, Po A, Petroni M, Ferretti E, Mori M, De Smaele E, Canettieri G, **Capalbo C**, Maroder M, Screpanti I, Kool M, Pfister SM, Guardavaccaro D, Gulino A, Di Marcotullio L.

Nat Commun. 2018 Mar 7;9(1):976. doi: 10.1038/s41467-018-03339-0. IF:11.8

A possible role of FANCM mutations in male breast cancer susceptibility: Results from a multicenter study in Italy.

Silvestri V, Rizzolo P, Zelli V, Valentini V, Zanna I, Bianchi S, Tibiletti MG, Varesco L, Russo A, Tommasi S, Coppa A, **Capalbo C**, Calistri D, Viel A, Cortesi L, Manoukian S, Bonanni B, Montagna M, Palli D, Radice P, Peterlongo P, Ottini L.

Breast. 2018 Apr;38:92-97. doi: 10.1016/j.breast.2017.12.013. Epub 2018 Jan 4. IF:3.4

Optimizing the identification of risk-relevant mutations by multigene panel testing in selected hereditary breast/ovarian cancer families.

Coppa A, Nicolussi A, D'Inzeo S, **Capalbo C**, Belardinilli F, Colicchia V, Petroni M, Zani M, Ferraro S, Rinaldi C, Buffone A, Bartolazzi A, Screpanti I, Ottini L, Giannini G.

Cancer Med. 2018 Jan;7(1):46-55. doi: 10.1002/cam4.1251. Epub 2017 Dec 22. IF:3.3

Next-generation sequencing: recent applications to the analysis of colorectal cancer.

Del Vecchio F, Mastroiaco V, Di Marco A, Compagnoni C, Capece D, Zazzeroni F, **Capalbo C**, Alesse E, Tessitore A.

J Transl Med. 2017 Dec 8;15(1):246. doi: 10.1186/s12967-017-1353-y. Review. IF: 4

Development of hepatocellular cancer induced by long term low fat-high carbohydrate diet in a NAFLD/NASH mouse model.

Tessitore A, Mastroiaco V, Vetuschi A, Sferra R, Pompili S, Ciciarelli G, Barnabei R, Capece D, Zazzeroni F, **Capalbo C**, Alesse E.

Oncotarget. 2017 Jun 21;8(32):53482-53494. doi: 10.18632/oncotarget.18585. eCollection 2017 Aug 8. IF: 4.7

Cancer secretome and inflammation: The bright and the dark sides of NF- κ B.

Capece D, Verzella D, Tessitore A, Alesse E, **Capalbo C**, Zazzeroni F.

Semin Cell Dev Biol. 2018 Jun;78:51-61. doi: 10.1016/j.semcdb.2017.08.004. Epub 2017 Aug 2. Review. IF:5.4

Corrigendum: Selective targeting of HDAC1/2 elicits anticancer effects through Gli1 acetylation in preclinical models of SHH Medulloblastoma.

Coni S, Mancuso AB, Di Magno L, Sdruscia G, Manni S, Serrao SM, Rotili D, Spiombi E, Bufalieri F, Petroni M, Kusio-Kobialka M, De Smaele E, Ferretti E, **Capalbo C**, Mai A, Niewiadomski P, Screpanti I, Di Marcotullio L, Canettieri G.

Sci Rep. 2017 Apr 21;7:46645. doi: 10.1038/srep46645. No abstract available. IF: 4

PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma.

Colicchia V, Petroni M, Guarguaglini G, Sardina F, Sahún-Roncero M, Carbonari M, Ricci B, Heil C, **Capalbo C**, Belardinilli F, Coppa A, Peruzzi G, Screpanti I, Lavia P, Gulino A, Giannini G.

Oncogene. 2017 Aug 17;36(33):4682-4691. doi: 10.1038/onc.2017.40. Epub 2017 Apr 10. IF: 6.6

Noncanonical GLI1 signaling promotes stemness features and in vivo growth in lung adenocarcinoma.

Po A, Silvano M, Miele E, **Capalbo C**, Eramo A, Salvati V, Todaro M, Besharat ZM, Catanzaro G, Cucchi D, Coni S, Di Marcotullio L, Canettieri G, Vacca A, Stassi G, De Smaele E, Tartaglia M, Screpanti I, De Maria R, Ferretti E.

Oncogene. 2017 Aug 10;36(32):4641-4652. doi: 10.1038/onc.2017.91. Epub 2017 Apr 3. IF: 6.6

The role of peroxiredoxins in cancer.

Nicolussi A, D'Inzeo S, **Capalbo C**, Giannini G, Coppa A.

Mol Clin Oncol. 2017 Feb;6(2):139-153. doi: 10.3892/mco.2017.1129. Epub 2017 Jan 10.

Selective targeting of HDAC1/2 elicits anticancer effects through Gli1 acetylation in preclinical models of SHH Medulloblastoma.

Coni S, Mancuso AB, Di Magno L, Sdruscia G, Manni S, Serrao SM, Rotili D, Spiombi E, Bufalieri F, Petroni M, Kusio-Kobialka M, De Smaele E, Ferretti E, **Capalbo C**, Mai A, Niewiadomski P, Screpanti I, Di Marcotullio L, Canettieri G.

Sci Rep. 2017 Mar 9;7:44079. doi: 10.1038/srep44079. Erratum in: Sci Rep. 2017 Apr 21;7:46645. IF: 4

Effect of MTHFR Polymorphisms on Gastrointestinal Cancer Risk in Italy.

Mazucca F, Borro M, Botticelli A, Aimati L, Gentile G, **Capalbo C**, Maddalena C, Mazzotti E, Simmaco M, Marchetti P.

World J Oncol. 2015 Aug;6(4):394-397. doi: 10.14740/wjon930w. Epub 2015 Aug 27.

Validation of the Ion Torrent PGM sequencing for the prospective routine molecular diagnostic of colorectal cancer.

Belardinilli F, **Capalbo C**, Buffone A, Petroni M, Colicchia V, Ferraro S, Zani M, Nicolussi A, D'Inzeo S, Coppa A, Screpanti I, Gulino A, Giannini G.

Clin Biochem. 2015 Sep;48(13-14):908-10. doi: 10.1016/j.clinbiochem.2015.04.003. Epub 2015 Apr 11. IF:2.4

Novel and recurrent BRCA2 mutations in Italian breast/ovarian cancer families widen the ovarian cancer cluster region boundaries to exons 13 and 14.

Coppa A, Buffone A, **Capalbo C**, Nicolussi A, D'Inzeo S, Belardinilli F, Colicchia V, Petroni M, Granato T, Midulla C, Zani M, Ferraro S, Screpanti I, Gulino A, Giannini G.

Breast Cancer Res Treat. 2014 Dec;148(3):629-35. doi: 10.1007/s10549-014-3196-z. Epub 2014 Nov 14. IF:3.4

Association of SULT1A1 Arg²¹³His polymorphism with male breast cancer risk: results from a multicenter study in Italy.

Ottini L, Rizzolo P, Zanna I, Silvestri V, Saieva C, Falchetti M, Masala G, Navazio AS, **Capalbo C**, Bianchi S, Manoukian S, Barile M, Peterlongo P, Caligo MA, Varesco L, Tommasi S, Russo A, Giannini G, Cortesi L, Cini G, Montagna M, Radice P, Palli D.

Breast Cancer Res Treat. 2014 Dec;148(3):623-8. doi: 10.1007/s10549-014-3193-2. Epub 2014 Nov 11. IF:3.4

Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer: a case report.

Capalbo C, Marchetti P, Coppa A, Calogero A, Anastasi E, Buffone A, Belardinilli F, Gulino M, Frati P, Catalano C, Cortesi E, Giannini G, Gulino A.

Cancer Biol Ther. 2014 Jul;15(7):826-31. doi: 10.4161/cbt.28878. Epub 2014 Apr 22. IF:2.8

Galectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors.

Veschi V, Petroni M, Bartolazzi A, Altavista P, Dominici C, **Capalbo C**, Boldrini R, Castellano A, McDowell HP, Pizer B, Frati L, Screpanti I, Gulino A, Giannini G.

Cell Death Dis. 2014 Mar 6;5:e1100. doi: 10.1038/cddis.2014.68. IF:5.9

PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms.

Nicolussi A, D'Inzeo S, Mincione G, Buffone A, Di Marcantonio MC, Cotellese R, Cichella A, **Capalbo C**, Di Gioia

C, Nardi F, Giannini G, Coppa A.

Int J Oncol. 2014 Feb;44(2):548-56. doi: 10.3892/ijo.2013.2208. Epub 2013 Dec 5. IF:3.5

High-throughput microRNA profiling of pediatric high-grade gliomas.

Miele E, Buttarelli FR, Arcella A, Begalli F, Garg N, Silvano M, Po A, Baldi C, Carissimo G, Antonelli M, Spinelli GP, **Capalbo C**, Donofrio V, Morra I, Nozza P, Gulino A, Giangaspero F, Ferretti E.

Neuro Oncol. 2014 Jan;16(2):228-40. doi: 10.1093/neuonc/not215. Epub 2013 Dec 4. IF:10

microRNA-17-92 cluster is a direct Nanog target and controls neural stem cell through Trp53inp1.

Garg N, Po A, Miele E, Campese AF, Begalli F, Silvano M, Infante P, **Capalbo C**, De Smaele E, Canettieri G, Di Marcotullio L, Screpanti I, Ferretti E, Gulino A.

EMBO J. 2013 Oct 30;32(21):2819-32. doi: 10.1038/emboj.2013.214. Epub 2013 Sep 27. IF:11.2

PCAF ubiquitin ligase activity inhibits Hedgehog/Gli1 signaling in p53-dependent response to genotoxic stress.

Mazzà D, Infante P, Colicchia V, Greco A, Alfonsi R, Siler M, Antonucci L, Po A, De Smaele E, Ferretti E, **Capalbo C**, Bellavia D, Canettieri G, Giannini G, Screpanti I, Gulino A, Di Marcotullio L.

Cell Death Differ. 2013 Dec;20(12):1688-97. doi: 10.1038/cdd.2013.120. Epub 2013 Sep 6. IF:8

The end of the beginning of personalized medicine.

Natoli G, **Capalbo C**.

Ann Oncol. 2011 Dec;22(12):2695. doi: 10.1093/annonc/mdr430. Epub 2011 Sep 23. IF:14.1

HER2-positive male breast cancer: an update.

Ottini L, **Capalbo C**, Rizzolo P, Silvestri V, Bronte G, Rizzo S, Russo A.

Breast Cancer (Dove Med Press). 2010 Oct 4;2:45-58. doi: 10.2147/BCTT.S6519. Review. IF:2

Clinical classification of BRCA1 DNA missense variants: H1686Q is a novel pathogenic mutation occurring in the ontogenetically invariant THV motif of the N-terminal BRCT domain.

Giannini G, **Capalbo C**, Ottini L, Buffone A, De Marchis L, Margaria E, Vitolo D, Ricevuto E, Rinaldi C, Zani M, Ferraro S, Marchetti P, Cortesi E, Frati L, Screpanti I, Gulino A.

J Clin Oncol. 2008 Sep 1;26(25):4212-4; author reply 4214-5. doi: 10.1200/JCO.2008.18.2089. IF:28.2

Does the search for large genomic rearrangements impact BRCAPRO carrier prediction?

Capalbo C, Buffone A, Vestri A, Ricevuto E, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A, Giannini G.

J Clin Oncol. 2007 Jun 20;25(18):2632-4; author reply 2634-5. IF:28.2

Prevalence of BRCA1 and BRCA2 genomic rearrangements in a cohort of consecutive Italian breast and/or ovarian cancer families.

Buffone A, **Capalbo C**, Ricevuto E, Sidoni T, Ottini L, Falchetti M, Cortesi E, Marchetti P, Scambia G, Tomao S, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A, Giannini G.

Breast Cancer Res Treat. 2007 Dec;106(2):289-96. Epub 2007 Feb 28. IF:3.4

Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.

Giannini G, **Capalbo C**, Ristori E, Ricevuto E, Sidoni T, Buffone A, Cortesi E, Marchetti P, Scambia G, Tomao S, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A.

Breast Cancer Res Treat. 2006 Nov;100(1):83-91. Epub 2006 May 9. IF:3.4

BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and

prevalence and analysis of mutation prediction models.

Capalbo C, Ricevuto E, Vestri A, Ristori E, Sidoni T, Buffone O, Adamo B, Cortesi E, Marchetti P, Scambia G, Tomao S, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A, Giannini G.
Ann Oncol. 2006 Jun;17 Suppl 7:vii34-40. IF:14.1

Improving the accuracy of BRCA1/2 mutation prediction: validation of the novel country-customized IC software.

Capalbo C, Ricevuto E, Vestri A, Sidoni T, Buffone A, Cortesi E, Marchetti P, Scambia G, Tomao S, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A, Giannini G.
Eur J Hum Genet. 2006 Jan;14(1):49-54. IF:3.6

A case of long surviving metastatic retroperitoneal epithelioid sarcoma in a 20 year old male.

Lauro S, Trasatti L, Conti A, **Capalbo C**, Della RC, Vecchione A.
J Exp Clin Cancer Res. 2003 Sep;22(3):491-4. IF:5.6


Solitary splenic recurrence of epithelial ovarian cancer: a case report and review.

Lauro S, Trasatti L, **Capalbo C**, Conti A, Ricci F, Mingazzini PL, Vecchione A.
Anticancer Res. 2002 Nov-Dec;22(6B):3643-5. IF:1.9

Unique pineal gland metastasis of clear cell renal carcinoma: case report and review of the literature.

Lauro S, Trasatti L, **Capalbo C**, Mingazzini PL, Vecchione A, Bosman C.
Anticancer Res. 2002 Sep-Oct;22(5):3077-9. Review. IF:1.9

- IF: Impact factor 2019.

Dott. Carlo Capalbo


Rome, 15/02/2020